Phase 2
Completed N=5
The Effect of Bevacizumab (Avastin) on Pterygium
Source: ClinicalTrials.gov NCT00592176 ↗Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Jun 2012
Primary outcomePrimary: The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection. — 5.75 area in millimeters squared — p=0.83
Summary
The purpose of this study is to determine whether local injection of bevacizumab might halt and or cause regression of pterygium growth. This may enable earlier treatment and prevention of pterygium growth into the patient's line of sight thereby limiting the need for surgery and improving quality of life for patients with pterygia.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection. |
5.75 | 0.83 |
| SECONDARY Number of Patients Having Surgical Removal of Pterygium. |
— | — |
Eligibility Criteria
Inclusion Criteria
- 19 years of age and older
- Diagnosis of pterygia
- healthy enough to make scheduled follow-up visits
Exclusion Criteria
- Women of childbearing potential and males who plan to father a child during their participation in the study will be excluded from the study.
Data sourced from ClinicalTrials.gov (NCT00592176). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.